Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Intelligent Bio SolutionsINBS -3.04%50 3-Year EBITDA Growth Rate is 81.40% as of Jun. 2026, which is 148% above its 10-year median of 32.80. GuruFocus rates INBS with a GF Score™ of 50/100 and a GF Value™ of $2.31 (Fairly Valued). The stock has 2 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Intelligent Bio Solutions ranks better than 96.22% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 81.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 70.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Intelligent Bio Solutions was 81.40% per year. The lowest was -20.10% per year. And the median was 32.80% per year.
Intelligent Bio Solutions (NAS:INBS) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Intelligent Bio Solutions 3-Year EBITDA Growth Rate Related Terms
INBS vs BMRA, VNRX, NXL: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Intelligent Bio Solutions's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intelligent Bio Solutions 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Intelligent Bio Solutions's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Intelligent Bio Solutions's 3-Year EBITDA Growth Rate falls into.
Intelligent Bio Solutions 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 81.40% mean?
Intelligent Bio Solutions (INBS) has a 3-Year EBITDA Growth Rate of 81.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Intelligent Bio Solutions and its competitors. This is 148% above median its historical median of 32.80. According to the industry distribution chart, Intelligent Bio Solutions ranks #26 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 3.8%.
Is Intelligent Bio Solutions' 3-Year EBITDA Growth Rate too high?
Intelligent Bio Solutions' current 3-Year EBITDA Growth Rate of 81.40% is 148% above median its 10-year median of 32.80. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.90. Intelligent Bio Solutions' value of 81.40% is 930.4% above this industry median. Based on the distribution chart, Intelligent Bio Solutions ranks #26 out of 688 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Intelligent Bio Solutions has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Intelligent Bio Solutions' 3-Year EBITDA Growth Rate compare to BMRA and VNRX?
According to the Medical Devices & Instruments industry distribution chart, Intelligent Bio Solutions ranks #26 out of 688 companies for 3-Year EBITDA Growth Rate. This places Intelligent Bio Solutions in the top 4% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 7.90. Intelligent Bio Solutions' value of 81.40% is 930.4% above this benchmark. While the company's 10-year median is 32.80 vs. the industry median of 7.90, Intelligent Bio Solutions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.90, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intelligent Bio Solutions's current 3-Year EBITDA Growth Rate of 81.40% is 930.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Intelligent Bio Solutions and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intelligent Bio Solutions's current 3-Year EBITDA Growth Rate is 81.40%, which is 148% above median its own 10-year median of 32.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intelligent Bio Solutions stock overvalued right now?
Based on GuruFocus' analysis, Intelligent Bio Solutions (INBS) is currently considered Fairly Valued. The stock's GF Value™ is $2.31, compared to a current price of $2.22 — trading 3.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 81.40%, which is 148% above median its 10-year median of 32.80 and 930.4% above the Medical Devices & Instruments industry median of 7.90. Intelligent Bio Solutions' overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Intelligent Bio Solutions (INBS), the current 3-Year EBITDA Growth Rate is 81.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intelligent Bio Solutions (INBS) Overvalued in 2026?
Based on GuruFocus' analysis, Intelligent Bio Solutions stock appears to be undervalued.
The current stock price of $2.22 is trading 3.9% below its estimated GF Value™ of $2.31.
GuruFocus considers Intelligent Bio Solutions to be Fairly Valued.
Key valuation signals for INBS:
3-Year EBITDA Growth Rate: 81.40% (148% above median its 10-year median of 32.80)
GF Value™: $2.31 vs. price of $2.22 (3.9% below fair value)
Industry Position: 930.4% above the Medical Devices & Instruments median (#26 of 688)
No single metric tells the full story. See the INBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
50GF Score
Get the complete analysis for INBS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBS has been successfully added to your 
